| Autor: |
Ip, A., Rosenthal, A., Mutebi, A., Wang, T., Jun, M., Wang, A., Yu, J., Brodkin, S., Sacchi, M., Kalsekar, A., Munoz, J. |
| Předmět: |
|
| Zdroj: |
Hematological Oncology; Jun2023 Supplement S2, Vol. 41, p433-434, 2p |
| Abstrakt: |
B Introduction: b There is currently no clear standard of care for patients with relapsed or refractory (R/R) large B-cell lymphoma (LBCL) who have failed >=2 prior lines of therapy (LOTs); although chemoimmunotherapy (CIT) regimens are the most commonly used therapies, outcomes are not optimal. Overall response rate (ORR) and complete response (CR) rate were compared using weighted logistic models, and progression-free survival (PFS) and overall survival (OS) were compared using weighted Cox proportional-hazard models. Comparison of clinical outcomes in patients with relapsed/refractory large B-cell lymphoma treated with epcoritamab versus chemoimmunotherapy. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
Plný text